Previously, a peptide from citrullinated histone-4 from activated neutrophils has been shown to be targets for ACPA in sera from patients with RA [8] with increased antibody levels years before and after symptom onset of RA, compared with controls [8, 11]. The gene discussed is PRTN3; the disease is rheumatoid arthritis.